This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
Candidates for treatment with carboplatin plus paclitaxel 1st line
Performance status (ECOG 0-2)
Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)
Patients with renal impairment (KDOQI 3-5)
Patients who do not have computed tomography study at baseline
Uncontrolled blood pressure (> 140 mmHg)
Uncontrolled diabetes (> 130 mg / dL)